Skip to main content

Year: 2022

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

Preclinical data demonstrate potential efficacy and safety of OV329 at low, chronic dosing, suggesting an improved profile compared to other GABA-aminotransferase inhibitorsData from the NIH/NINDs Epilepsy Therapy Screening Program demonstrate that OV329 confers protection from seizure activity in several treatment-resistant animal modelsNew preclinical data on OV350 underscore the potential of activating the KCC2 to alleviate refractory status epilepticus and limit neuronal damageNEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant...

Continue reading

Verizon helps L.A. Comic Con attendees get their game on

Verizon unlocks exciting video game experiences for Los Angeles Comic Con attendees from Dec. 2-4 NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) — Verizon will be participating in this year’s Los Angeles Comic Con, with a booth at the Gaming Stage within the Los Angeles Convention Center. Throughout the three-day event, pop culture and gaming fans have the opportunity to score in-game items for the world’s most-played PC game, League of Legends. Attendees can visit the Verizon booth to earn a card containing a download code for a League of Legends Masterwork Chest and Key. After redeeming, players can unlock the Masterwork Chest and possibly gain valuable loot, such as new champions, epic skins and other items. Developed by Riot Games, League of Legends, commonly known as League, is a competitive 5v5 multiplayer online battle...

Continue reading

Correction: Form 8.3 – Horizon Therapeutics plc

                        FORM 8.3   IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION  Name of person dealing (Note 1) State Street Global Advisors & AffiliatesCompany dealt in Horizon Therapeutics plcClass of relevant security to which the dealings being disclosed relate (Note 2) $0.0001 ordinary sharesDate of dealing 30th Nov 2022       2. INTERESTS AND SHORT POSITIONS   (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)    Long Short  Number (%) Number (%)(1) Relevant securities 5,974,957 2.63582%    (2) Derivatives (other than options) 508 0.000224%    (3) Options and agreements to purchase/sell N/A N/A    Total 5,975,465 2.63605%        (b)...

Continue reading

JBS USA Enters Agreement to Acquire Certain Assets From TriOak Foods

Agreement Cements Longstanding Exclusive Partnership GREELEY, Colo., Dec. 02, 2022 (GLOBE NEWSWIRE) — JBS USA, a leading global food company, announced it has reached an agreement to acquire certain assets from TriOak Foods, a Midwest-based pork producer, for an undisclosed amount. The two companies enjoy a long-standing business relationship, with JBS USA serving as the exclusive customer of TriOak market hogs since 2017. A family operation established in 1951, TriOak Foods includes live pork production, grain merchandising and fertilizer marketing. Agricultural real estate assets in Iowa are not included in the transaction. A leader in on-farm sustainability, TriOak Foods hog farms include multiple open pen gestation facilities and farms compliant with California’s Proposition 12 rule. “Today’s announcement is aligned with our...

Continue reading

Notice of redemption of convertible bonds PKG5

Notice of redemption of convertible bonds PKG5 AS Pro Kapital Grupp informs that it is redeeming 24 500 “EEK 7.00 PRO KAPITAL GRUPP CONV. BOND PKG5 10-2020” convertible bonds (with ISINEE3300109917) in total nominal value of 245 000 Estonian kroons and issue value of 68 600 euros and has submitted the Nasdaq Central Depository of Securities the application to delete the bonds from the register. The convertible bonds bore an annual interest of 7%. The issue price of each convertible bond was 2.80 euros. The list of bondholders was fixed on 29 November 2022 and redemption payment will be made on 13 December 2022.   Edoardo Axel Preatoni Member of the Management Board +372 614 4920prokapital@prokapital.ee  

Continue reading

Notice of redemption of convertible bonds PKG5

Notice of redemption of convertible bonds PKG5 AS Pro Kapital Grupp informs that it is redeeming 24 500 “EEK 7.00 PRO KAPITAL GRUPP CONV. BOND PKG5 10-2020” convertible bonds (with ISINEE3300109917) in total nominal value of 245 000 Estonian kroons and issue value of 68 600 euros and has submitted the Nasdaq Central Depository of Securities the application to delete the bonds from the register. The convertible bonds bore an annual interest of 7%. The issue price of each convertible bond was 2.80 euros. The list of bondholders was fixed on 29 November 2022 and redemption payment will be made on 13 December 2022.Edoardo Axel Preatoni Member of the Management Board +372 614 4920prokapital@prokapital.ee  

Continue reading

Stelmine acquires three new properties in the de Caniapiscau district

QUEBEC CITY, Dec. 02, 2022 (GLOBE NEWSWIRE) — Stelmine Canada (« Stelmine ») (TSXV : STH). Stelmine maintains its aggressive strategy of acquiring mining properties in the Caniapiscau mining district. The Company is adding 326 new claims to his portfolio bringing the total to 1775 claims covering 936 km2. This scenario allows the Company to protect his dominant land position and develop this new district while taking advantage of high potential mineral targets. In addition to the gold potential, the mineralization discovered on these three new properties should help Stelmine reach its objective of diversifying its portfolio and actively engage in the exploration of strategic metals such as nickel and some base metals while pursuing the advancement of its gold properties. Undoubtedly, during the last five years, Stelmine took the...

Continue reading

Horizon Therapeutics plc

                        FORM 8.3   IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION  Name of person dealing (Note 1) State Street Global Advisors & AffiliatesCompany dealt in Horizon Therapeutics plcClass of relevant security to which the dealings being disclosed relate (Note 2) $0.0001 ordinary sharesDate of dealing 01st Dec 2022       2. INTERESTS AND SHORT POSITIONS   (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)    Long Short  Number (%) Number (%)(1) Relevant securities 5,916,453 2.61001%    (2) Derivatives (other than options) 508 0.000224%    (3) Options and agreements to purchase/sell N/A N/A    Total 5,916,961 2.61024%        (b)...

Continue reading

Horizon Therapeutics plc

                        FORM 8.3   IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION  Name of person dealing (Note 1) State Street Global Advisors & AffiliatesCompany dealt in Horizon Therapeutics plcClass of relevant security to which the dealings being disclosed relate (Note 2) $0.0001 ordinary sharesDate of dealing 29th Nov 2022       2. INTERESTS AND SHORT POSITIONS   (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)    Long Short  Number (%) Number (%)(1) Relevant securities 5,889,421 2.59809%    (2) Derivatives (other than options) 508 0.000224%    (3) Options and agreements to purchase/sell N/A N/A    Total 5,889,929 2.59831%        (b)...

Continue reading

CareCloud To Host Virtual Analyst and Investor Day

SOMERSET, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) — CareCloud, Inc. (the “Company”) (Nasdaq: MTBC, MTBCO, MTBCP), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced they will host an inaugural Analyst and Investor Day from 1 to 3 p.m. EST on Monday, December 12, 2022 using a live webcast. CareCloud leadership team will use this virtual event to share with participants their historic vision to transform the healthcare industry through high-quality technology, world-class operations and exciting new products. For 20 years, CareCloud has been a pillar in the healthcare technology space, helping healthcare providers deliver a premium, high-value experience for every patient. The Company is at the forefront of the industry’s shift to digitization and a value-based care model, with...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.